Edwards Lifesciences Corporation reported a significant increase in financial performance for the first quarter of 2026, with net sales reaching $1.65 billion, a 16.7% increase from $1.41 billion in the same period of 2025. The company's gross profit also rose to $1.29 billion, up from $1.11 billion year-over-year. However, the gross profit margin decreased slightly due to foreign currency fluctuations and increased manufacturing costs associated with new product expansions. Net income attributable to Edwards Lifesciences was $380.7 million, or $0.66 per diluted share, compared to $358.0 million, or $0.61 per diluted share, in the prior year.
The company experienced notable growth across its product lines, particularly in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). TAVR sales increased by 14.4% to $1.20 billion, driven by higher demand for the Edwards SAPIEN 3 Ultra valve. TMTT sales surged by 51.9% to $175.1 million, reflecting strong performance from the PASCAL and EVOQUE systems. Additionally, Edwards Lifesciences expanded its geographic reach, with sales outside the United States growing by 23.9% to $711 million.
Strategically, Edwards Lifesciences completed the acquisition of Autus Valve Technologies, Inc. in February 2026 for $128.9 million, with potential additional payments of up to $132.5 million based on performance milestones. This acquisition is expected to enhance the company's capabilities in pediatric heart valve solutions. The company also divested its Critical Care product group in September 2024 and a non-core product group in December 2025, focusing its efforts on core structural heart disease innovations.
Operationally, Edwards Lifesciences reported a decrease in cash and cash equivalents to $2.45 billion as of March 31, 2026, down from $2.94 billion at the end of 2025. The company’s employee headcount increased to support its growth initiatives, contributing to a rise in selling, general, and administrative expenses, which totaled $522.2 million for the quarter. The company also faced a loss on impairment of $123.6 million related to one of its variable interest entity investments, impacting its overall financial results.
Looking ahead, Edwards Lifesciences remains optimistic about its growth trajectory, driven by ongoing product innovation and market expansion. The company anticipates continued demand for its TAVR and TMTT products, alongside the integration of Autus into its operations. However, it acknowledges potential challenges from market conditions, including inflation and trade policy impacts, which may affect future performance. The company is committed to navigating these challenges while focusing on delivering innovative solutions for patients with structural heart disease.
About Edwards Lifesciences Corp
Edwards Lifesciences is a global leader in structural heart disease solutions, specializing in innovative surgical and transcatheter therapies for valve repair and replacement. Its core products include transcatheter aortic valves, mitral and tricuspid repair systems, and surgical tissue valves. Serving patients worldwide, the company emphasizes clinical evidence, product innovation, and partnerships to improve outcomes and address the growing burden of cardiovascular disease.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.